Completed PHASE4 INTERVENTIONAL 6-arm NCT05053126

Study Evaluating Abuse Potential of Lyrica® in Healthy Non-Drug Dependent Recreational Opioid Users

A Phase 4 Randomized Double-Blind Double-Dummy Placebo & Active-Controlled Single-Dose Six-Way Crossover Study Evaluating the Abuse Potential of Lyrica® Taken Orally With Oxycodone HCL in Healthy Non-Drug Dependent Recreational Opioid Users

Sponsor: Viatris Specialty LLC

Conditions Abuse Potential

Interventions Placebo Pregabalin 300 mg with oxycodone 20 mg Pregabalin 300mg oxycodone 20 mg pregabalin 450 mg pregabalin 450 mg with oxycodone 20 mg

Updated 6 times since 2021 Last updated: Jul 21, 2023 Started: Jul 27, 2021 Primary completion: Apr 1, 2022 Completion: Apr 1, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Abuse Potential, this trial is completed. The trial is conducted by Viatris Specialty LLC and has accumulated 6 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Sep 2023 — Jul 2024 [monthly]

Completed PHASE4
Feb 2023 — Sep 2023 [monthly]

Completed PHASE4

Status: Recruiting → Completed
Apr 2022 — Feb 2023 [monthly]

Recruiting PHASE4

▶ Show 1 earlier version

Oct 2021 — Apr 2022 [monthly]

Recruiting PHASE4

First recorded

Jul 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Viatris Specialty LLC

Data source: Viatris Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Marlton, United States